Role of chemotherapy and biomolecular therapy in the treatment of uterine sarcomas.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Best Practice & Research: Clinical Obstetrics & Gynaecology

• Publication date

  2011-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.bpobgyn.2011.06.003PMID 21752717
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Role of trabectedin (T) in the management of advanced uterine leiomyosarcoma (U-LM).

  2016cited by this paper
• Aromatase inhibitor anastrozole as a second-line hormonal treatment to a recurrent low-grade endometrial stromal sarcoma: a case report

  2011cited by this paper
• Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors.

  2010cited by this paper
• Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study.

  2010cited by this paper
• Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus.

  2010cited by this paper
• A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study.

  2010cited by this paper
• Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients

  2009cited by this paper
• Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles.

  2009cited by this paper
• Temozolomide in Advanced and Recurrent Uterine Leiomyosarcoma and Correlation With O6-Methylguanine DNA Methyltransferase Expression: A Case Series

  2009cited by this paper
• Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

  2009cited by this paper
• Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.

  2009cited by this paper
• Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).

  2009cited by this paper
• Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.

  2009cited by this paper
• A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma.

  2008cited by this paper
• Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.

  2008cited by this paper
• Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.

  2008cited by this paper
• Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874).

  2008cited by this paper
• Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study.

  2007cited by this paper
• A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.

  2007cited by this paper
• A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.

  2007cited by this paper
• HELLP Syndrome: A Rare, Early Presentation at 17 Weeks of Gestation

  2007cited by this paper
• Phase I/II study of docetaxel (D), gemcitabine (G), and bevacizumab (B) in patients (pts) with advanced or recurrent soft tissue sarcoma (STS)

  2007cited by this paper
• A multi-institutional review of outcomes of endometrial stromal sarcoma.

  2007cited by this paper
• Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium.

  2006cited by this paper
• A Clinicopathologic Study

  2006cited by this paper
• Aromatase inhibitors (AI) are highly effective in uterine sarcomas (US) expressing estrogen receptors.

  2006cited by this paper
• Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial.

  2005cited by this paper
• ClinicalStudy Phase II Study of Temozolomide and Thalidomide in Patients with Unresectable or Metastatic Leiomyosarcoma

  2005cited by this paper
• The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study.

  2005cited by this paper
• Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study.

  2005cited by this paper
• Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.

  2005cited by this paper
• Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.

  2005cited by this paper
• Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study.

  2005cited by this paper
• Temozolomide in uterine leiomyosarcomas.

  2005cited by this paper
• Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study.

  2004cited by this paper
• Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.

  2004cited by this paper
• The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990-1999) at the Massachusetts General Hospital.

  2004cited by this paper
• Low-grade endometrial stromal sarcoma treated with the aromatase inhibitor letrozole.

  2004cited by this paper
• Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma

  2004cited by this paper
• Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy in localized uterine sarcomas: results of a case-control study with radiotherapy alone

  2004cited by this paper
• Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

  2004cited by this paper
• De novo uterine sarcoma with good response to neo-adjuvant chemotherapy

  2003cited by this paper
• Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.

  2003cited by this paper
• Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study.

  2003cited by this paper
• Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?

  2002cited by this paper
• Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: a phase II study of the Gynecologic Oncology Group.

  2002cited by this paper
• Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

  2002cited by this paper
• Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study.

  2001cited by this paper
• Prognostic parameters in endometrial stromal sarcoma: a clinicopathologic study in 31 patients.

  2001cited by this paper
• Endometrial stromal sarcoma: objective response to letrozole.

  2001cited by this paper
• Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study.

  2000cited by this paper
• A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study.

  2000cited by this paper
• Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study.

  1998cited by this paper
• Treatment of stage IV "high-grade" endometrial stromal sarcoma with ifosfamide, adriamycin, and cisplatin.

  1997cited by this paper
• Phase II trial of paclitaxel in leiomyosarcoma of the uterus: a gynecologic oncology group study.

  1996cited by this paper
• Phase II trial of etoposide in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.

  1996cited by this paper
• Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study.

  1996cited by this paper
• The prognostic significance of surgery, tumor size, malignancy grade, menopausal status, and DNA ploidy in endometrial stromal sarcoma.

  1996cited by this paper
• A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group study.

  1994cited by this paper
• Phase II trial of ifosfamide and mesna in leiomyosarcoma ofthe uterus: A Gynecologic Oncology Group study

  1992cited by this paper
• Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.

  1992cited by this paper
• Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study.

  1991cited by this paper
• Uterine sarcoma: steroid receptors and response to hormonal therapy.

  1990cited by this paper
• Mitoxantrone in the Treatment of Advanced Uterine Sarcoma: A Phase II Trial of the Gynecologic Oncology Group

  1990cited by this paper
• Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study).

  1989cited by this paper
• Treatment of Uterine Leiomyosarcoma

  1988cited by this paper
• Cisplatin therapy for disseminated mixed mesodermal sarcoma of the uterus.

  1987cited by this paper
• High‐dose doxorubicin infusion therapy for disseminated mixed mesodermal sarcoma of the uterus

  1987cited by this paper
• Endometrial stromal sarcoma: a clinicopathologic study of 11 cases with determination of estrogen and progestin receptor levels in three tumors.

  1987cited by this paper
• Phase II trial of etoposide in the management of advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study.

  1987cited by this paper
• Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study.

  1986cited by this paper
• Endolymphatic stromal myosis: a case with positive estrogen and progesterone receptors and good response to progestins.

  1985cited by this paper
• Phase II trial of piperazinedione in patients with advanced or recurrent uterine sarcoma: A Gynecologic Oncology Group study

  1985cited by this paper
• A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study.

  1985cited by this paper
• Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin Versus doxorubicin and cyclophosphamide (a phase III trial of the gynecologic oncology group)

  1985cited by this paper
• Cytoplasmic estrogen and progesterone receptor content of uterine sarcomas.

  1984cited by this paper
• A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas

  1983cited by this paper
• Treatment, results and prognostic factors in stage I and II sarcomas of the corpus uteri.

  1976cited by this paper

• Uterine leiomyosarcoma.

  2025cites this paper
• Clinical guidelines for diagnosis, treatment and monitoring of patients with malignant tumors of uterine corpus

  2021cites this paper
• Upregulated MELK Leads to Doxorubicin Chemoresistance and M2 Macrophage Polarization via the miR-34a/JAK2/STAT3 Pathway in Uterine Leiomyosarcoma

  2020cites this paper
• ERKRANKUNGEN DES BLUTES UND DES GERINNUNGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE

  2020cites this paper
• Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in seven patients with peritoneal sarcomatosis from uterine sarcoma

  2018cites this paper
• Significance of Lymphovascular Space Invasion by the Sarcomatous Component in Uterine Carcinosarcoma

  2018cites this paper
• Uterine Corpus Cancer

  2018cites this paper
• Multi-institutional study of peritoneal sarcomatosis from uterine sarcoma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

  2017cites this paper
• Chemoembolization in the treatment of metastasis from uterine sarcoma to the spine

  2017cites this paper
• Distant Metastases in Uterine Leiomyosarcomas: The Wide Variety of Body Sites and Time Intervals to Metastatic Relapse

  2017cites this paper
• Endometrial stromal sarcoma in combination with mixed type endometrial carcinomas

  2017cites this paper
• Uterine sarcoma Part II-Uterine endometrial stromal sarcoma: The TAG systematic review.

  2016cites this paper
• Pioglitazone induces cell growth arrest and activates mitochondrial apoptosis in human uterine leiomyosarcoma cells by a peroxisome proliferator-activated receptor γ-independent mechanism

  2016cites this paper
• PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma

  2016cites this paper
• Improved clinical trial enrollments for uterine leiomyosarcoma patients after gynecologic oncology partnership with a sarcoma center.

  2016cites this paper
• Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12

  2016cites this paper
• Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy.

  2016cites this paper
• Uterine Sarcoma, Version 1.2016: Featured Updates to the NCCN Guidelines.

  2015cites this paper
• Role of Systemic Therapy in the Management of Uterine Sarcomas

  2015cites this paper
• Recent advances in the treatment of sarcomas in gynecology.

  2014cites this paper
• [Clinicopathologic characteristics and prognosis factors of uterine sarcomas in central Tunisia].

  2014cites this paper
• Uterine neoplasms, version 1.2014.

  2014cites this paper
• Caractéristiques clinicopathologiques et facteurs pronostiques des sarcomes utérins dans le centre tunisien

  2014cites this paper
• Pathologic prognostic factors in stage I–III uterine carcinosarcoma treated with postoperative radiotherapy

  2014cites this paper
• Uterine Sarcomas in the Elderly

  2013cites this paper
• Long lasting clinical response to chemotherapy for advanced uterine leiomyosarcoma: a case report

  2013cites this paper
• Uncommon Tumors of the Esophagus

  2012cites this paper
• Uterine carcinosarcoma, leiomyosarcoma and endometrial stromal sarcoma : Epidemiological, clinical and prognostic aspects

  2012influential citation
• [Uterine carcinosarcoma].

  2012cites this paper
• Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP 53 , ATRX , and MED 12 Makinen

  year unknowncites this paper